Adaptimmune Therapeutics Plc - ADR

+0.05 (+0.87%)
Products, Strategic Combinations

Adaptimmune Enters Into Strategic Collaboration With Genentech

Published: 09/07/2021 13:49 GMT
Adaptimmune Therapeutics Plc - ADR (ADAP) - :adaptimmune Enters Into Strategic Collaboration With Genentech to Research, Develop, Commercialize Cancer-targeted Allogeneic T-cell Therapies.
Adaptimmune - Collaboration Covers Development of Novel Allogeneic Personalized Cell Therapy Platform.
Adaptimmune - Genentech Will Be Responsible for Input Tcrs & Subsequent Clinical Development, Commercialization.
Adaptimmune - Will Receive Upfront Payment of $150 Million, Additional Payments of $150 Million Over 5 Yrs, Unless Agreement is Earlier Terminated.
Adaptimmune - Co to Be Responsible for Developing Clinical Candidates Using Its Ipsc Derived Allogeneic Platform to Produce T-cells.
Adaptimmune - Collaboration Covers Research & Development of “off-the-shelf” Cell Therapies for Up to 5 Shared Cancer Targets.
Adaptimmune - May Be Eligible to Receive Milestones Payments Potentially Exceeding $3 Billion in Aggregate Value.
Adaptimmune - Will Also Receive Tiered Royalties on Net Sales in Mid-single to Low-double Digits.
Adaptimmune - Has Right to Opt in to a 50/50 U.S. Profit/cost Share on "off-the-shelf" Products.
Further Company Coverage: Adapo ((reuters.